BR112016007100A2 - tratamento contra tumor combinado usando interferon gama e minicélulas carregadas com fármaco dirigidas a ligantes biespecíficos - Google Patents

tratamento contra tumor combinado usando interferon gama e minicélulas carregadas com fármaco dirigidas a ligantes biespecíficos

Info

Publication number
BR112016007100A2
BR112016007100A2 BR112016007100A BR112016007100A BR112016007100A2 BR 112016007100 A2 BR112016007100 A2 BR 112016007100A2 BR 112016007100 A BR112016007100 A BR 112016007100A BR 112016007100 A BR112016007100 A BR 112016007100A BR 112016007100 A2 BR112016007100 A2 BR 112016007100A2
Authority
BR
Brazil
Prior art keywords
gamma
composition
tumor treatment
interferon gamma
minicells
Prior art date
Application number
BR112016007100A
Other languages
English (en)
Inventor
Brahmbhatt Himanshu
Macdiarmid Jennifer
Original Assignee
Engeneic Molecular Delivery Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engeneic Molecular Delivery Pty Ltd filed Critical Engeneic Molecular Delivery Pty Ltd
Publication of BR112016007100A2 publication Critical patent/BR112016007100A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

“tratamento contra tumor combinado usando interferon gama e minicélulas carregadas com fármaco dirigidas a ligantes biespecíficos” resumo a presente invenção refere-se a composições e métodos para tratamentos contra o câncer. a metodologia envolve, por exemplo, administrar a um paciente com câncer uma primeira composição, que compreende várias minicélulas bacterianamente derivadas intactas ou células bacterianas mortas intactas, cada uma das quais contém um agente anti-neoplásico e carrega um ligante na superfície, o ligante tendo especificidade por um receptor de superfície de célula mamífera não fagócita, e uma segunda composição, que compreende um interferon-gama (ifn-gama) ou um agente que aumenta a expressão do ifn-gama no paciente. as composições incluem a primeira composição e a segunda composição, conforme descritas, opcionalmente com agentes anti-neoplásicos adicionais. 20/1 1/1
BR112016007100A 2013-10-04 2014-10-03 tratamento contra tumor combinado usando interferon gama e minicélulas carregadas com fármaco dirigidas a ligantes biespecíficos BR112016007100A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361887258P 2013-10-04 2013-10-04
PCT/IB2014/002824 WO2015049589A1 (en) 2013-10-04 2014-10-03 Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma

Publications (1)

Publication Number Publication Date
BR112016007100A2 true BR112016007100A2 (pt) 2017-08-01

Family

ID=52777107

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016007100A BR112016007100A2 (pt) 2013-10-04 2014-10-03 tratamento contra tumor combinado usando interferon gama e minicélulas carregadas com fármaco dirigidas a ligantes biespecíficos

Country Status (17)

Country Link
US (2) US9731011B2 (pt)
EP (1) EP3052122A4 (pt)
JP (1) JP6538031B2 (pt)
KR (1) KR102433719B1 (pt)
CN (1) CN105658233B (pt)
AP (1) AP2016009153A0 (pt)
AU (1) AU2014330895B2 (pt)
BR (1) BR112016007100A2 (pt)
CA (1) CA2926161C (pt)
EA (1) EA032740B1 (pt)
HK (1) HK1223281A1 (pt)
IL (1) IL244851B (pt)
MX (1) MX2016004285A (pt)
NZ (1) NZ718148A (pt)
SG (1) SG11201602429QA (pt)
TW (1) TWI737576B (pt)
WO (1) WO2015049589A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3052122A4 (en) * 2013-10-04 2017-05-17 EnGeneIC Molecular Delivery Pty Ltd. Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma
CA2963218C (en) * 2014-10-03 2023-10-24 Engeneic Molecular Delivery Pty Ltd Enhanced loading of intact, bacterially derived vesicles with small molecule compounds
MA46469A (fr) * 2016-10-06 2019-08-14 Engeneic Molecular Delivery Pty Ltd Minicellules bactériennes pour l'administration d'adjuvants d'acides nucléiques et leurs procédés d'utilisation
CA3069523A1 (en) 2017-07-11 2019-01-17 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
EP3446710A1 (en) * 2017-08-25 2019-02-27 Glenmark Pharmaceuticals S.A. Methods of inactivating viral contaminants
KR20210030973A (ko) 2018-07-11 2021-03-18 액팀 테라퓨틱스, 인코퍼레이티드 조작된 면역자극성 박테리아 균주 및 이의 용도
WO2020021437A1 (en) * 2018-07-23 2020-01-30 Engeneic Molecular Delivery Pty Ltd Compositions comprising bacterially derived minicells and methods of using the same
CA3125702A1 (en) * 2019-01-04 2020-07-09 Engeneic Molecular Delivery Pty Ltd Encapsulated glycolipid antigens for treatment of neoplastic diseases
JP2023518484A (ja) * 2020-03-24 2023-05-01 エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド コロナウイルス感染症を含むウイルス感染症を治療および／または予防するための組成物およびワクチン、並びにそれらの使用方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2315067B (en) 1996-07-11 2000-02-16 Pharmacia Spa Morpholinyl anthracycline derivatives
CN1367701A (zh) 1999-05-11 2002-09-04 奥索－麦克尼尔药物公司 红细胞生成素给药的药代动力学和药效模型
JP2003513681A (ja) * 1999-11-12 2003-04-15 マキシゲン・ホールディングス・リミテッド インターフェロンガンマ・コンジュゲート
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
ES2584305T3 (es) 2001-10-15 2016-09-27 Engeneic Molecular Delivery Pty Ltd. Minicélulas intactas como vectores para transferencia de ADN y terapia génica in vitro e in vivo
EP1594547A2 (en) * 2003-02-14 2005-11-16 University Of South Florida Research Foundation, Inc. Chitosan-microparticles for ifn gene delivery
US7611885B2 (en) 2003-06-24 2009-11-03 Engeneic Molecular Delivery Pty, Ltd. Pharmaceutically compatible method for purifying intact bacterial minicells
CA2549840C (en) 2003-12-09 2012-03-20 Engeneic Molecular Delivery Pty Ltd. Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells
SG135174A1 (en) * 2004-02-02 2007-09-28 Engeneic Molecular Delivery Pty Ltd Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
US8772013B2 (en) 2004-02-02 2014-07-08 Engeneic Molecular Delivery Pty Ltd Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
EP1791959A4 (en) * 2004-08-26 2009-03-18 Enegenic Gene Therapy Pty Ltd DISPOSAL OF FUNCTIONAL NUCLEIC ACIDS ON MAMMALIAN CELLS OVER BACTERIA ORIGINAL INTACT MINIMIZERS
CA2803995C (en) 2004-08-26 2014-06-10 Engeneic Molecular Delivery Pty Ltd. Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells
CN101505768B (zh) 2006-06-23 2013-11-06 因詹尼克分子递送控股有限公司 通过完整的死亡细菌细胞将药物、治疗性核酸和功能性核酸靶向递送至哺乳动物细胞
PL2145002T3 (pl) 2007-03-30 2015-06-30 Engeneic Molecular Delivery Pty Ltd Nienaruszone minikomórki pochodzenia bakteryjnego, które obejmują funkcjonalny kwas nukleinowy pozbawiony plazmidu do dostarczania in vivo do komórek ssaczych
KR101897307B1 (ko) 2010-12-02 2018-09-10 네르비아노 메디칼 사이언시스 에스.알.엘. 모르폴리닐 안트라사이클린 유도체의 제조 방법
HUE052136T2 (hu) * 2011-12-13 2021-04-28 Engeneic Molecular Delivery Pty Ltd Bakteriális eredetû intakt minisejtek terápiás szerek agydaganatokba történõ bejuttatására
CN104837506A (zh) * 2012-10-02 2015-08-12 瓦克星治疗有限责任公司 免疫调节性小细胞及使用方法
EP3052122A4 (en) * 2013-10-04 2017-05-17 EnGeneIC Molecular Delivery Pty Ltd. Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma

Also Published As

Publication number Publication date
US20170326235A1 (en) 2017-11-16
NZ718148A (en) 2022-02-25
US9731011B2 (en) 2017-08-15
TW201601748A (zh) 2016-01-16
CN105658233B (zh) 2020-09-04
AU2014330895A1 (en) 2016-04-14
CN105658233A (zh) 2016-06-08
IL244851A0 (en) 2016-05-31
EP3052122A4 (en) 2017-05-17
WO2015049589A1 (en) 2015-04-09
US10500277B2 (en) 2019-12-10
EA032740B1 (ru) 2019-07-31
HK1223281A1 (zh) 2017-07-28
US20150098897A1 (en) 2015-04-09
JP2016532639A (ja) 2016-10-20
JP6538031B2 (ja) 2019-07-03
TWI737576B (zh) 2021-09-01
MX2016004285A (es) 2016-07-08
KR20160058885A (ko) 2016-05-25
EA201690680A1 (ru) 2016-07-29
KR102433719B1 (ko) 2022-08-17
SG11201602429QA (en) 2016-04-28
IL244851B (en) 2020-04-30
AU2014330895B2 (en) 2019-08-15
AP2016009153A0 (en) 2016-04-30
EP3052122A1 (en) 2016-08-10
CA2926161A1 (en) 2015-04-09
CA2926161C (en) 2023-03-14

Similar Documents

Publication Publication Date Title
BR112016007100A2 (pt) tratamento contra tumor combinado usando interferon gama e minicélulas carregadas com fármaco dirigidas a ligantes biespecíficos
MX2017007321A (es) Terapias de combinacion.
BR112017008042A2 (pt) métodos e composições para dosagem em terapia de célula adotiva
MY166014A (en) Combination therapy methods for treating proliferative diseases
BR112018067379A2 (pt) conjugado anticorpo-droga, composição, método para tratamento de um paciente que tem ou corre o risco de ter um câncer, para produzir o conjugado anticorpo-droga ou a composição, para determinar se um paciente será responsivo a um tratamento com o conjugado anticorpo-droga ou a composição, e, uso de um conjugado anticorpo-droga ou de uma composição.
CO2017011536A2 (es) Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo
CO6670567A2 (es) Métodos de tratamiento contra el cáncer pancreático
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
SG10201811841UA (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
CO7101246A2 (es) Compuesto de carbamato y preparación y uso de los mismos
BR112015000660A8 (pt) uso de uma terapia de primeira linha e uma terapia de segunda linha para tratamento de um paciente possuindo uma doença, desordem ou condição associada com uma expressão elevada de um antígeno de tumor, e de uma composição para reduzir ou evitar um efeito adverso associado com a administração de uma célula geneticamente modificada para expressar um car.
BR112018070580A2 (pt) métodos e composições para terapia com células t car
BR112016011169A2 (pt) Método para a produção de células imunes ex vivo que são resistentes a um fármaco análogo de purina, célula t isolada resistente a um análogo de purina, composição farmacêutica e uso das mesmas
PE20150223A1 (es) Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos
BR112012024442A2 (pt) métodos de tratamento de câncer
BR112015006176A8 (pt) método de tratamento de câncer em um indivíduo com necessidade de tratamento
BR112016012713A2 (pt) Método para tratamento de câncer em um paciente necessitado, e, método de selecionar um paciente para um método de tratamento
BR112018073518A2 (pt) métodos para sensibilização de células de câncer a um tratamento anticâncer, para potencialização do efeito terapêutico de um tratamento anticâncer e para tratamento de câncer, composição, modulador de canais de ânion regulados por volume, kit de peças, e, uso de um modulador de canais de ânion regulados por volume
AR074203A1 (es) Terapia anti-angiogenesis para el tratamiento del cancer de mama. kit. uso.
MX2021012272A (es) Metodos y composiciones para tratar el cancer e incrementar la inmunidad terapeutica reduciendo selectivamente los monocitos m2 inmunomoduladores.
PH12020550598A1 (en) Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
BR112021017878A2 (pt) Carbonato de magnésio com superfície reagida, sistema de liberação, formulação de cuidados domiciliares, métodos para preparar um carbonato de magnésio com superfície reagida e para preparar um sistema de liberação, e, uso de um carbonato de magnésio com superfície reagida e de um sistema de liberação
CR10996A (es) Metodo de tratamiento del cancer mediante administracion de combinaciones de il-18 humana
MX2021001084A (es) Terapia de combinacion para el tratamiento del cancer.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]